Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 6/20 | 0.48 |
| ▸ | TCF7L2 | Q9NQB0 | 6/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886891 | 0.95 | TP53 (0.44) | CTNNB1TCF7L2TP53LMNAHTR7 | |
| SCHEMBL5887641 | 0.92 | MAPT (0.44) | CTNNB1TCF7L2TP53LMNAHTR7 | |
| SCHEMBL5887425 | 0.92 | HTR7 (0.45) | CTNNB1TCF7L2TP53LMNAHTR7 | |
| SCHEMBL5887548 | 0.91 | KMT2A (0.46) | CTNNB1TCF7L2TP53LMNAMAPT | |
| SCHEMBL5887117 | 0.91 | SMN1; SMN2 (0.49) | CTNNB1TCF7L2TP53HTR7 | |
| SCHEMBL5886779 | 0.91 | MAPT (0.44) | CTNNB1TCF7L2TP53LMNAMAPT | |
| SCHEMBL5886882 | 0.90 | MAPT (0.43) | TP53LMNAMAPT | |
| SCHEMBL5886707 | 0.90 | ALDH1A1 (0.46) | CTNNB1TCF7L2TP53LMNAMAPT | |
| SCHEMBL5887414 | 0.90 | CCR1 (0.43) | CTNNB1TCF7L2LMNAMAPT | |
| SCHEMBL5886918 | 0.90 | CTNNB1 (0.43) | CTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | CTNNB1 1452/4885TCF7L2 381/4885TP53 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.